---
document_datetime: 2025-12-02 05:00:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/arzerra.html
document_name: arzerra.html
version: success
processing_time: 0.1125
conversion_datetime: 2025-12-25 00:28:30.806502
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Arzerra

[RSS](/en/individual-human-medicine.xml/65840)

##### Withdrawn

This medicine's authorisation has been withdrawn

ofatumumab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Arzerra](#news-on)
- [More information on Arzerra](#more-information-on-arzerra-536)
- [More information on Arzerra](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 28 February 2019, the European Commission withdrew the marketing authorisation for Arzerra (ofatumumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Novartis Europharm Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Arzerra was granted marketing authorisation in the EU on 19 April 2010 for the treatment of chronic lymphocytic leukaemia (CLL). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2015.

The European Public Assessment Report (EPAR) for Arzerra is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Arzerra : EPAR - Summary for the public

English (EN) (529.97 KB - PDF)

**First published:** 14/06/2010

**Last updated:** 02/10/2017

[View](/en/documents/overview/arzerra-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-237)

български (BG) (639.47 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/bg/documents/overview/arzerra-epar-summary-public_bg.pdf)

español (ES) (529.69 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/es/documents/overview/arzerra-epar-summary-public_es.pdf)

čeština (CS) (605.37 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/cs/documents/overview/arzerra-epar-summary-public_cs.pdf)

dansk (DA) (526.59 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/da/documents/overview/arzerra-epar-summary-public_da.pdf)

Deutsch (DE) (530.74 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/de/documents/overview/arzerra-epar-summary-public_de.pdf)

eesti keel (ET) (525.22 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/et/documents/overview/arzerra-epar-summary-public_et.pdf)

ελληνικά (EL) (645 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/el/documents/overview/arzerra-epar-summary-public_el.pdf)

français (FR) (530.34 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/fr/documents/overview/arzerra-epar-summary-public_fr.pdf)

hrvatski (HR) (550.17 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/hr/documents/overview/arzerra-epar-summary-public_hr.pdf)

italiano (IT) (525.56 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/it/documents/overview/arzerra-epar-summary-public_it.pdf)

latviešu valoda (LV) (601.3 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/lv/documents/overview/arzerra-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (562.92 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/lt/documents/overview/arzerra-epar-summary-public_lt.pdf)

magyar (HU) (606.24 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/hu/documents/overview/arzerra-epar-summary-public_hu.pdf)

Malti (MT) (601.91 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/mt/documents/overview/arzerra-epar-summary-public_mt.pdf)

Nederlands (NL) (528.75 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/nl/documents/overview/arzerra-epar-summary-public_nl.pdf)

polski (PL) (614.43 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/pl/documents/overview/arzerra-epar-summary-public_pl.pdf)

português (PT) (529.49 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/pt/documents/overview/arzerra-epar-summary-public_pt.pdf)

română (RO) (559.74 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/ro/documents/overview/arzerra-epar-summary-public_ro.pdf)

slovenčina (SK) (600.96 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/sk/documents/overview/arzerra-epar-summary-public_sk.pdf)

slovenščina (SL) (592.67 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/sl/documents/overview/arzerra-epar-summary-public_sl.pdf)

Suomi (FI) (525.59 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/fi/documents/overview/arzerra-epar-summary-public_fi.pdf)

svenska (SV) (527.01 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

02/10/2017

[View](/sv/documents/overview/arzerra-epar-summary-public_sv.pdf)

## Product information

Arzerra : EPAR - Product Information

English (EN) (1.03 MB - PDF)

**First published:** 14/06/2010

**Last updated:** 22/08/2017

[View](/en/documents/product-information/arzerra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-594)

български (BG) (2.51 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/bg/documents/product-information/arzerra-epar-product-information_bg.pdf)

español (ES) (1.46 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/es/documents/product-information/arzerra-epar-product-information_es.pdf)

čeština (CS) (2.04 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/cs/documents/product-information/arzerra-epar-product-information_cs.pdf)

dansk (DA) (1.48 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/da/documents/product-information/arzerra-epar-product-information_da.pdf)

Deutsch (DE) (1.47 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/de/documents/product-information/arzerra-epar-product-information_de.pdf)

eesti keel (ET) (1.38 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/et/documents/product-information/arzerra-epar-product-information_et.pdf)

ελληνικά (EL) (2.58 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/el/documents/product-information/arzerra-epar-product-information_el.pdf)

français (FR) (1.45 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/fr/documents/product-information/arzerra-epar-product-information_fr.pdf)

hrvatski (HR) (1.5 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/hr/documents/product-information/arzerra-epar-product-information_hr.pdf)

íslenska (IS) (1.4 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/is/documents/product-information/arzerra-epar-product-information_is.pdf)

italiano (IT) (1.11 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/it/documents/product-information/arzerra-epar-product-information_it.pdf)

latviešu valoda (LV) (2.08 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/lv/documents/product-information/arzerra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.15 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/lt/documents/product-information/arzerra-epar-product-information_lt.pdf)

magyar (HU) (2.14 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/hu/documents/product-information/arzerra-epar-product-information_hu.pdf)

Malti (MT) (2.22 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/mt/documents/product-information/arzerra-epar-product-information_mt.pdf)

Nederlands (NL) (1.55 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/nl/documents/product-information/arzerra-epar-product-information_nl.pdf)

norsk (NO) (1.33 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/no/documents/product-information/arzerra-epar-product-information_no.pdf)

polski (PL) (2.04 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/pl/documents/product-information/arzerra-epar-product-information_pl.pdf)

português (PT) (1.37 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/pt/documents/product-information/arzerra-epar-product-information_pt.pdf)

română (RO) (1.57 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/ro/documents/product-information/arzerra-epar-product-information_ro.pdf)

slovenčina (SK) (2.07 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/sk/documents/product-information/arzerra-epar-product-information_sk.pdf)

slovenščina (SL) (1.95 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/sl/documents/product-information/arzerra-epar-product-information_sl.pdf)

Suomi (FI) (1.33 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/fi/documents/product-information/arzerra-epar-product-information_fi.pdf)

svenska (SV) (1.52 MB - PDF)

**First published:**

14/06/2010

**Last updated:**

22/08/2017

[View](/sv/documents/product-information/arzerra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0051 02/10/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Arzerra : EPAR - All Authorised presentations

English (EN) (461.05 KB - PDF)

**First published:** 14/06/2010

**Last updated:** 05/08/2014

[View](/en/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-531)

български (BG) (499.43 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/bg/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_bg.pdf)

español (ES) (463.19 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/es/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (481.28 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/cs/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (456.65 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/da/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (451.69 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/de/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (455.91 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/et/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (538.02 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/el/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_el.pdf)

français (FR) (456.78 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/fr/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (516.79 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/hr/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (454.34 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/is/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (455.89 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/it/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (487.34 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/lv/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (566.09 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/lt/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (474.45 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/hu/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (470.85 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/mt/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (453.25 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/nl/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (454.78 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/no/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_no.pdf)

polski (PL) (529.8 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/pl/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_pl.pdf)

português (PT) (483.59 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/pt/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_pt.pdf)

română (RO) (495.54 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/ro/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (519.11 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/sk/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (503.38 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/sl/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (458.87 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/fi/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (477.82 KB - PDF)

**First published:**

14/06/2010

**Last updated:**

05/08/2014

[View](/sv/documents/all-authorised-presentations/arzerra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Arzerra Active substance ofatumumab International non-proprietary name (INN) or common name ofatumumab Therapeutic area (MeSH) Leukemia, Lymphocytic, Chronic, B-Cell Anatomical therapeutic chemical (ATC) code L01XC10

### Pharmacotherapeutic group

Monoclonal antibodies

### Therapeutic indication

**Previously untreated chronic lymphocytic leukaemia (CLL)** : Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.

**Relapsed CLL** : Arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL.

**Refractory CLL** : Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.

## Authorisation details

EMA product number EMEA/H/C/001131 Marketing authorisation holder

Novartis Europharm Ltd

Frimley Business Park

Marketing authorisation issued 19/04/2010 Withdrawal of marketing authorisation 28/02/2019 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Arzerra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (637.29 KB - PDF)

**First published:** 08/04/2011

**Last updated:** 22/08/2017

[View](/en/documents/procedural-steps-after/arzerra-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Arzerra-H-C-1131-II-0045 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/692752/2016

English (EN) (5.64 MB - PDF)

**First published:** 08/02/2017

**Last updated:** 08/02/2017

[View](/en/documents/variation-report/arzerra-h-c-1131-ii-0045-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Arzerra

Adopted

Reference Number: EMA/CHMP/693024/2016

English (EN) (505.24 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arzerra_en.pdf)

Arzerra-H-C-1131-II-41 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/77370/2016

English (EN) (3.7 MB - PDF)

**First published:** 24/08/2016

**Last updated:** 24/08/2016

[View](/en/documents/variation-report/arzerra-h-c-1131-ii-41-epar-assessment-report-variation_en.pdf)

Questions and answers on refusal of a change to the marketing authorisation for Arzerra (ofatumumab)

Adopted

Reference Number: EMA/433595/2016

English (EN) (512.37 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-arzerra-ofatumumab_en.pdf)

Arzerra-H-C-1131-II-0023 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/475698/2014

English (EN) (2.37 MB - PDF)

**First published:** 05/08/2014

**Last updated:** 05/08/2014

[View](/en/documents/variation-report/arzerra-h-c-1131-ii-0023-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Arzerra

Adopted

Reference Number: EMA/CHMP/312178/2014

English (EN) (506.82 KB - PDF)

**First published:** 23/05/2014

**Last updated:** 23/05/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arzerra_en.pdf-0)

## Initial marketing authorisation documents

Arzerra : EPAR - Public assessment report

English (EN) (1.58 MB - PDF)

**First published:** 14/06/2010

**Last updated:** 14/06/2010

[View](/en/documents/assessment-report/arzerra-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Arzerra

Adopted

Reference Number: EMA/CHMP/21426/2010

English (EN) (511.39 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 22/01/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-arzerra_en.pdf)

#### News on Arzerra

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2016) 16/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-may-2014) 23/05/2014

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC001131II0041) (variation II/0041)

#### More information on Arzerra

- [The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European Medicines Agency Committee for Medicinal Products for Human Use](http://theoncologist.alphamedpress.org/content/15/12/1335.long)

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-08-581) on 7 November 2008. Arzerra was withdrawn from the Community register of orphan medicinal products in December 2018 upon request of the marketing authorisation holder.

#### More information on Arzerra

- [Arzerra - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/arzerra)
- [Drug Use Investigation for Arzerra Chronic Lymphocytic Leukemia (CLL) (116789) - post-authorisation study](https://catalogues.ema.europa.eu/study/48996)

**This page was last updated on** 10/05/2019

## Share this page

[Back to top](#main-content)